Strides Pharma Science reported a strong Q3FY26 with record quarterly EBITDA of ₹2,359m, a 12.2% year-over-year increase. Operational PAT grew by approximately 39% year-over-year, reaching ₹1,282m, with an EPS of ₹13.9. Revenue growth was tepid at 3.6%, offset by robust performance in ex-US markets, expanding by 20% year-over-year.
Financial Highlights
Strides Pharma Science has announced its financial results for Q3FY26, demonstrating significant growth in profitability. Key highlights include:
- EBITDA: Reached ₹2,359m, a 12.2% increase compared to Q3FY25.
- Operational PAT: Stood at ₹1,282m, with EPS at ₹13.9, reflecting an approximate 39% year-over-year growth.
- Gross Margin: Expanded by 280bps year-over-year.
- EBITDA Margin: Increased by 160bps year-over-year, reaching 19.8%.
9MFY26 Performance Overview
The company’s performance over the nine months of FY26 also showcased growth across key metrics:
- Revenue: Grew by 4.7% to ₹35,352m.
- Gross Margin: Increased by 11.6% to ₹21,127m.
- EBITDA: Rose by 17.2% to ₹6,856m.
- Operational PAT: Substantially increased by 65.0% to ₹3,824m.
- Operational EPS: Increased by 64.7% to ₹41.5.
US Market Performance
Q3FY26 revenue in the US market remained steady at $70m despite new market entrants. The company launched four products during the first nine months of the financial year. Future growth will be supported by a revenue target of ~$400m by FY28, driven by relaunched products and new segments, including nasal sprays.
Ex-US Markets Growth
Ex-US markets demonstrated strong growth, with revenue increasing by 20% year-over-year. Q3FY26 revenue reached $64m. This growth was primarily driven by key markets in Australia, the UK, and EU. The Other Regulated Markets (ORM) grew 21% year-over-year, while Growth Markets increased by 19% year-over-year.
Leadership Updates
The company welcomed Peter Hardwick as the new CEO of North America and Nandini Matiyani as Executive Vice President – Human Resources.
Source: BSE
